Innocan Pharma closes private placement

1 minute read
31 December 2020
Client work

Team:

Jason Saltzman, Joseph McDonald, J. Quinn Clement-Schlimm

On December 31, 2020, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) closed a non-brokered private placement offering of units for aggregate gross proceeds of $2,367,804.

Innocan is an Israeli pharmaceutical technology company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD") with other pharmaceutical ingredients.

Gowling WLG advised Innocan with respect to this private placement with a team that included Jason A. Saltzman, Joseph McDonald and Quinn Clement-Schlimm.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Cannabis, Corporate Commercial, Capital Markets

Team

Related Insights & Resources

View all insights Related Insights & Resources
Client work
14 March 2024 Innocan Pharma closes non-brokered private placement
paperclip chain Articles
31 January 2024 Supply chain transparency reporting begins in Canada
Client work
15 January 2024 Red White & Bloom Brands transitions to international cannabis company through closing of Aleafia transaction

Team

Download or print PDF